absence of an anti-inflammatory agent; and reducing said adverse physiological reaction.

25. (Amended) A [liposome] composition comprising a liposome [and a bioactive agent which is] in combination with an anti-inflammatory agent not contained in the liposome.

29. (Amended) A [liposome] composition comprising a liposome composition [and a bioactive agent which is a contrast agent], in combination with an anti-inflammatory agent wherein the liposome composition comprises a contrast agent.

Claim 33, line before "agent" insert --modifying-- and delete "modified molecule".

Claim 36, line 1, replace "25" with --33--.

Claim 37, line 1, replace "25" with --33--.

Claim 38, line 1, replace "25" with --33--.

Claim 41, line 1, replace "25" with --33--.

43. (Amended) The composition of claim 25, wherein the liposome comprises a lipid bilayer having a lipid and a surface modified molecule, said surface agent modified molecule [comprises] comprising a phospholipid anchor having a glycerol backbone [anchor] and a spacer group and wherein the spacer group comprises a functional group capable of attaching to the glycerol backbone and a functional group capable of attaching to the phosphate group of the phospholipid anchor.

Please add new claims 45-53:

--45. A pharmaceutical composition comprising a bioactive agent containing liposome in combination with an anti-inflammatory agent.

46. The pharmaceutical composition of claim 45, wherein the bioactive agent is a contrast agent.

47. The pharmaceutical composition of claim 45, wehrein the anti-inflammatory agent is indomethacin.

48. The pharmaceutical composition of claim 45, wherein the liposome comprises a lipid bilayer having a lipid and a surface agent-modified molecule which comprises an anchor and a surface modifying agent, and wherein the liposome has an average diameter of from at least about 220 nm to about 5000 nm.

49. The pharmaceutical composition of claim 48, wherein the liposome has an average diameter of from about 400 nm to about 1000 nm.

50. The pharmaceutical composition of claim 48, wherein the surface modifying agent is a dicarboxylic acid, a monocarboxylic acid or a sulfolipid.

51. The pharmaceutical composition of claim 48, wherein the surface modifying agent is a dicarboxylic acid.

52. The pharmaceutical composition of claim 48, wherein the surface agent modified molecule comprises a phospholipid anchor having a glycerol backbone and a spacer group and wherein the spacer group comprises a functional group capable of attaching to the glycerol